Mode
Text Size
Log in / Sign up

Proenkephalin A levels show no correlation with kidney or cardiac markers in hemodialysis patientsPENK Levels Don't Predict Kidney Function in Dialysis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret PENK biomarker findings cautiously in ESKD due to lack of correlation with standard markers.

This prospective cohort study enrolled 100 adult patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis at a single center. The intervention involved measuring Proenkephalin A 119–159 (PENK) levels before and after a single hemodialysis session, with comparisons to estimated GFR (eGFR), BUN, SCr, NT-proBNP, and LVEF. The primary outcome assessed correlations between PENK and eGFR, as well as PENK clearance during hemodialysis.

Main results showed no significant correlations between PENK and eGFR (r = -0.00, p = 0.99), BUN (r = 0.16, p = 0.10), SCr (r = 0.18, p = 0.08), NT-proBNP (r = -0.06, p = 0.58), or LVEF (r = 0.12, p = 0.26) in the entire cohort. In a subgroup of 56 patients with residual urine output, PENK and eGFR also showed no significant correlation (r = -0.15, p = 0.28). BUN clearance during hemodialysis was significant (12.59 vs. 3.68 mmol/L, p < 0.05), but PENK clearance data were not reported.

Safety and tolerability were not reported. Key limitations include the single-center design and lack of reported funding or conflicts. The study notes associations only, with no causation claimed, and the clinical utility of PENK in ESKD remains to be established. Practice relevance is not reported, and findings should be interpreted cautiously due to the observational nature and limited generalizability.

  • High PENK levels do not predict kidney failure in dialysis patients.
  • This marker works for healthy kidneys, not those on machines.
  • Dialysis clears this protein, but it doesn't track your GFR.

When Your Kidneys Stop Working

Imagine your kidneys as a complex filtration plant. They clean your blood, remove waste, and balance fluids. When this plant fails completely, it is called end-stage kidney disease.

About 37 million people worldwide have chronic kidney disease. For many, the damage is so severe that their kidneys can no longer keep up. These patients need dialysis to survive.

Doctors currently use specific markers to track how well a patient's remaining kidney function is working. One of these markers is Proenkephalin A 119–159, often called PENK.

Why This Marker Failed Here

In people with healthy or partially working kidneys, high PENK levels usually mean the filtration rate is dropping. It acts like a warning light on a dashboard.

But here's the twist: this warning light does not work the same way when the engine is completely off.

A new study looked at 100 patients who were already on maintenance hemodialysis. These are people whose kidneys have stopped working well enough to need a machine.

Researchers measured PENK levels before and after a dialysis session. They also checked other common markers like creatinine and blood urea nitrogen.

The results were surprising for anyone hoping to use PENK in this setting. There was no link between PENK levels and the estimated glomerular filtration rate.

In plain English, the amount of PENK in the blood did not change based on how well the patient's kidneys were filtering. The numbers stayed flat regardless of the patient's condition.

This held true even for patients who still made some urine. In those cases, PENK levels still did not match their kidney function.

How Dialysis Changes The Picture

Think of dialysis as a powerful vacuum cleaner. It sucks waste out of your blood. During the session, the machine successfully removes PENK from the bloodstream.

However, removing the protein does not tell you how much waste is still sitting in your body. The study showed that while BUN (a waste product) dropped significantly, PENK levels did not provide useful data for doctors.

If you or a loved one is on dialysis, do not look for PENK tests to monitor your progress. These tests are designed for earlier stages of kidney disease.

Your medical team will continue to use standard tests like creatinine and eGFR. These tools remain the most reliable way to track your treatment.

The Limitations

This study only looked at patients on dialysis. It did not test people with early-stage kidney disease. That is where PENK is still very useful.

The researchers were clear: this marker is not a replacement for current methods in advanced kidney failure.

Doctors will keep using proven methods to manage dialysis patients. Research continues to find better ways to monitor health, but PENK is not one of them for this group.

Talk to your nephrologist about the best tests for your specific situation. They know your history and can guide you on what matters most.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundHigh levels of Proenkephalin A 119–159 (PENK) have been associated with decreased glomerular filtration rate (GFR) in subjects with preserved kidney function, yet its clinical utility in patients with end-stage kidney disease (ESKD) remains to be established. This study aimed to investigate the correlation between PENK and GFR, and evaluate the clearance of PENK during hemodialysis (HD) in ESKD patients.MethodsThis single-center prospective cohort study enrolled adult patients with ESKD undergoing maintenance HD. Plasma PENK levels were determined before (baseline) and after a single HD session using a double-antibody sandwich enzyme-linked immunosorbent assay. The associations of PENK with estimated GFR (eGFR), and other markers of kidney function and heart failure were analyzed at baseline. Furthermore, changes in PENK levels during HD were evaluated to assess its dialytic clearance.ResultsA total of 100 ESKD patients were enrolled. At baseline, the median eGFR and PENK level were 6.30 mL/min/1.73 m2 and 4.88 ng/mL, respectively. In the entire cohort (n = 100), no significant correlations were observed between PENK and eGFR (r = −0.00, p = 0.99), BUN (r = 0.16, p = 0.10), SCr (r = 0.18, p = 0.08), NT-proBNP (r = −0.06, p = 0.58), or LVEF (r = 0.12, p = 0.26). Among patients with residual urine output (n = 56), PENK and eGFR also exhibited no significant correlation (r = −0.15, p = 0.28). Although significant clearance was observed for BUN (12.59 vs. 3.68 mmol/L, p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.